Prestige Biopharma Designated as a Non-Compliant Disclosure Corporation

[Asia Economy Reporter Gong Byung-sun] Prestige Biopharma announced on the 6th that it has been designated as a non-compliant disclosure corporation by the Korea Exchange's KOSPI Market Division.

The reason for the non-compliant disclosure designation is the delayed disclosure of information related to the signing of a comprehensive contract for pharmaceutical contract manufacturing. The penalty for the disclosure violation is 16 million KRW.